Chronic myeloid leukemia (CML) has become a model in research and management among
malignant disorders. Since the discovery of the presence of a unique and constant …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Until now little information is available about bone marrow (BM) angiogenesis in chronic
myeloproliferative disorders (CMPDs). Amongst the various immunohistochemical markers …

Following the introduction of the WHO classification of chronic myeloproliferative disorders
(MPDs), after approximately 5 years, a critical reappraisal appears to be warranted …

Interferons (IFNs) are cellular glycoproteins with antiproliferative, antiviral, and
immunoregulatory properties. IFNs are produced by various cell types in response to viral …

Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive
(Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome …

目的: 研究α 干扰素联合阿糖胞苷对白血病K562 细胞的诱导凋亡作用及其作用机制. 方法:
以浓度2 000 U/ml 的α 干扰素与不同浓度的阿糖胞苷作用于体外培养的K562 细胞 …

Background: The Partners in Research program provides first-hand research experiences
for medical, pharmacy, and African-American undergraduate students. Methods: During ten …

Chronic myeloid leukemia is defined by the acquired genetic mutation, t (9; 22), which leads
to the fusion-protein BCR-ABL. Prior to the development of imatinib mesylate (Gleevec) …

Progress in the care of patients with leukemia has been one of the great success stories in
the field of oncology, and clinical research in leukemia has been the “flagship” of the Cancer …